News

2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Resverlogix Repays $68.8 Million Loan
Resverlogix Closes Previously Announced $87 Million Private Placement with Shenzhen Hepalink
Resverlogix Announces Participation in Upcoming Conferences
Resverlogix Announces Fifth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
Resverlogix Announces Right of First Refusal Agreement with Hepalink USA Inc.
Resverlogix Announces $87 Million Private Placement with Shenzhen Hepalink
Resverlogix Announces Annual and Special Meeting of Shareholders
Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis
Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
Successful CANTOS Inflammation Trial Supports Rationale for Resverlogix' Ongoing BETonMACE Trial
Resverlogix Announces Extension of Maturity Date of Loan and Expression of Interest Regarding Strategic Transaction
Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial
Resverlogix Files 2017 Year-End Disclosure Documents and Announces Plans to Host a Symposium at the European Society of Cardiology Congress 2017
Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial
Resverlogix Announces Fourth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
Resverlogix Comments on TSX Trader Notes
Resverlogix Closes $10 Million of Equity Subscriptions
Resverlogix to Raise Up To $10 Million
Resverlogix Announces Overnight Marketed Equity Offering
Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017
Resverlogix To Host Epigenetics Focused Symposium At The ERA-EDTA Congress in Madrid, Spain
Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone
Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success
Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial
Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corporate Activities
Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office
Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial
Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease
Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments
Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA